Definition |
ADT is the first-line treatment in hormone-sensitive metastatic PCa. The SIOG PCWG recommends evaluation of baseline bone mineral density and prevention of osteoporosis by calcium and vitamin D supplements. Routine bisphosphonates or denosumab to prevent skeletal complications in ADT is not recommended, unlessthere is a risk of fracture, or castration-resistant PCa (CRPC) with skeletal metastasis.
|